Piper Jaffray Starts Novan (NOVN) at Overweight

October 17, 2016 6:10 AM EDT
Get Alerts NOVN Hot Sheet
Price: $26.89 -0.33%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade NOVN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray initiates coverage on Novan (NASDAQ: NOVN) with a Overweight rating and a price target of $25.00.

Analyst David Amsellem commented, "We are initiating coverage of Novan Therapeutics with an Overweight rating and $25 PT. We believe that NOVN’s Nitricil platform, which has yielded a number of novel mid-tolate-stage pipeline shots-on-goal in the medical dermatology space, has the potential to drive transformative longer-term value creation. SB204 in particular could emerge as a differentiated topical, non-antibiotic option for moderate-to-severe acne (and a durable asset at that given that it is a new chemical entity (NCE) with patents that expire as late as 2034). We believe the product is well-positioned for Phase III success (data are expected in 1Q17) and further believe that peak sales of $300M+ are realistic. Given that backdrop, along with potential contribution from mid-stage opportunities SB206 and SB208, NOVN in our view is attractively valued in the context of a market cap of around $290M."

For an analyst ratings summary and ratings history on Novan click here. For more ratings news on Novan click here.

Shares of Novan closed at $18.97 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

Piper Jaffray

Add Your Comment